

**STable 3 Hierarchical analysis of correlation between LMR and PFS in lung cancer patients**

	No. of studies	Combined HR (95% CI)	P value	P <sub>interaction</sub> value	Heterogeneity		Residual heterogeneity
					P	I <sup>2</sup>	I <sup>2</sup>
<b>Total PFS</b>	11	1.49 (1.34, 1.67)	<0.01	—	0.77	0%	—
<i>Histology</i>							0%
NSCLC	10	1.49 (1.33, 1.68)	<0.01	0.96	0.68	0%	
SCLC	1	1.51 (1.06, 2.16)	0.02		—	—	
<i>Tumor stage</i>							0%
ED	6	1.48 (1.28, 1.72)	<0.01	0.98	0.27	21%	
LD	4	1.51 (1.25, 1.83)	<0.01		0.99	0%	
LD and ED	1	1.51 (1.06, 2.16)	0.02		—	—	
<i>Treatment</i>							24%
Chemotherapy	4	1.42 (1.22, 1.65)	<0.01	0.72	0.37	4%	
TKI	2	1.91 (1.27, 2.86)	<0.01		0.27	17%	
Chemotherapy+TKI	1	1.61 (1.19, 2.16)	<0.01		—	—	
Immunology	3	1.49 (1.12, 1.99)	<0.01		0.96	0%	
Chemotherapy+Radiotherapy	1	1.51 (1.06, 2.16)	0.02		—	—	
<i>Sample size</i>							0%
>300	3	1.41(1.20, 1.65)	<0.01	0.30	0.22	35%	
<300	8	1.58 (1.35, 1.85)	<0.01		0.94	0%	
<i>Cut-off value</i>							0%
>4	3	1.52 (1.28, 1.80)	<0.01	0.79	1.00	0%	
<4	8	1.48 (1.27, 1.71)	<0.01		0.49	0%	